Comprehensive ADME Overview Notes

Principles of Drug Absorption

  • Solubilization Requirements for Oral Absorption:

    • Solid dosage forms must dissolve into solution before systemic absorption can occur; the rate of dissolution often acts as the rate-limiting step for overall absorption.

    • Key physicochemical factors governing solubilization include degree of ionization (pH-dependent), molecular polar hydrophilicity, and overall molecular shape.

    • Polar molecules generally exhibit higher aqueous solubility, whereas non-polar lipophilic molecules exhibit higher membrane permeability.

  • Lipinski's Rule of 5:

    • Predicts that oral absorption is likely to be poor for a small molecule drug candidate if it violates more than one of the following thresholds:

      • There are more than 55 hydrogen bond donors (calculated as the sum of all NH\text{NH} and OH\text{OH} functional groups).

      • There are more than 1010 hydrogen bond acceptors (calculated as the sum of all N\text{N} and O\text{O} atoms).

      • The molecular weight (MrM_r) is greater than 500 g/mol500\,\text{g/mol}.

      • The calculated octanol-water partition coefficient (cLogP\text{cLog}P) is greater than 55.

  • Mechanisms of Membrane Transport:

    • Paracellular Diffusion: Movement between adjacent cells. Limited to small (Mr<350 g/molM_r < 350\,\text{g/mol}), polar drugs. Permeability varies significantly across tissue types depending on tight junctions (e.g., nasal epithelium is relatively leaky, whereas GI tract epithelium is tighter, and the blood-brain barrier contains extremely tight junctions).

    • Passive Lipid Diffusion: Uncharged lipophilic drugs pass directly through the phospholipid membrane bilayer. Governed by Fick's Law of Diffusion:

Flux across membrane=(C1−C2)×Area×PermeabilityThickness\text{Flux across membrane} = \frac{(C_1 - C_2) \times \text{Area} \times \text{Permeability}}{\text{Thickness}}

*   Passive permeability is governed by solubility in membrane lipid (lipid:water partition coefficient), charge/ionization state, mobility within membrane lipids (diffusion coefficient), and molecular mass (increased molecular mass reduces permeability).
*   **The Absorption Conflict:** Polar drugs possess high aqueous solubility (SS) but low membrane permeability, whereas lipophilic drugs possess high permeability (kak_a) but low aqueous solubility. Both factors directly drive total absorption across intestinal transit time (tsit_{si}) and small intestine volume (VsiV_{si}).
  • pH Trapping and the pH Partition Hypothesis:

    • Uncharged (unionized) molecules preferentially cross lipid membranes via passive diffusion.

    • Weak acids (AH\text{AH}) dissociate according to the equilibrium:

AH⇌A−+H+\text{AH} \rightleftharpoons \text{A}^- + \text{H}^+

*   Weak bases (B\text{B}) protonate according to the equilibrium:

BH+⇌B+H+\text{BH}^+ \rightleftharpoons \text{B} + \text{H}^+

*   In acidic environments (high [H+][\text{H}^+]), weak carboxyl acids (R-CO2H\text{R-CO}_2\text{H}) remain unionized and lipophilic, whereas weak amines (R-NH2\text{R-NH}_2) become ionized (R-NH3+\text{R-NH}_3^+). In alkaline environments, weak acids ionize to carboxylates (R-CO2−\text{R-CO}_2^-), whereas weak bases remain uncharged free bases.
*   Quantitative ionization ratios are calculated using the **Henderson-Hasselbalch Equations**:
    *   For weak acids:

pKa=pH+log⁡10([AH][A−]∣)\text{p}K_a = \text{pH} + \log_{10}\left(\frac{[\text{AH}]}{[\text{A}^-]|}\right)

    *   For weak bases:

pKa=pH+log⁡10([BH+][B])\text{p}K_a = \text{pH} + \log_{10}\left(\frac{[\text{BH}^+]}{[\text{B}]}\right)


Aspirin and Pethidine ion trapping across gastric, plasma, and urine compartments
  • Carrier-Mediated Transport & Specialized Pathways:

    • Can be active (energy-dependent, against a concentration gradient) or passive (facilitated diffusion).

    • Transporters exhibit structural specificity and saturability.

    • Critical for drug passage across the blood-brain barrier, gastrointestinal tract, renal tubules, biliary tract, and placenta.

    • Efflux Pumps: Efflux transporters such as P-glycoprotein (encoded by the MDR1MDR1 gene) in intestinal mucosal membranes pump absorbed drug molecules back into the GI lumen, reducing bioavailability.

    • Aquaporins: Transmembrane protein channels responsible for transporting water and small uncharged solutes across biological membranes; central to water reabsorption in renal tubules.

    • Pinocytosis: Vesicular engulfment of fluid or macromolecular solutes across cell membranes.

Factors Regulating Gastrointestinal and Parenteral Absorption

  • Anatomical and Physiological GI Factors:

    • Stomach: Small absorptive surface area (∼1 m2\sim 1\,\text{m}^2), highly acidic (pH 1−3.5\text{pH } 1 - 3.5). High acidity can cause chemical hydrolysis of acid-labile drugs.

    • Small Intestine: Principal site of oral drug absorption due to a massive surface area (∼200 m2\sim 200\,\text{m}^2 provided by villi and microvilli), high blood flow, and high epithelial permeability. Average transit time is ∼4 hours\sim 4\,\text{hours}.

    • Large Intestine (Colon): Intermediate surface area, alkaline environment (pH 8\text{pH } 8), with long transit times ranging from 10−36 hours10 - 36\,\text{hours}.


Anatomical regions of the gastrointestinal tract and corresponding pH values
  • Formulation & Chemical Binding Factors:

    • Chemical conversion into a lipophilic prodrug can bypass mucosal permeability barriers for highly polar drugs.

    • Chelation and binding to co-administered GI contents prevent absorption (e.g., binding of drugs to cholestyramine; chelation of tetracycline by polyvalent metal cations such as Mg2+\text{Mg}^{2+}, Ca2+\text{Ca}^{2+}, or Fe2+\text{Fe}^{2+}).

  • Gastric Emptying Rates:

    • Rapid gastric emptying accelerates drug delivery to the small intestine, increasing absorption rate.

    • Co-ingested food (especially high fat content) delays gastric emptying. Exception: Poorly soluble drugs exhibit enhanced absorption when taken with food due to prolonged residence time permitting complete dissolution.

  • Presystemic Metabolism & Efflux:

    • Drug degradation can occur via GI microflora, mucosal wall enzymes (Cytochrome P450 isoforms, Monoamine Oxidase), or hepatic first-pass metabolism via portal circulation.

    • Intestinal CYP3A4 activity can be inhibited by co-ingested substances (e.g., grapefruit juice), significantly elevating drug exposure.

  • Subcutaneous and Intramuscular Parenteral Sites:

    • Capillary endothelial walls are vastly more permeable than GI epithelial membranes, allowing polar compounds and macromolecules to readily reach capillary or lymphatic vessels.

    • Absorption rate is predominantly controlled by local tissue blood perfusion.

Mechanisms of Drug Distribution

  • Body Fluid Compartments:

    • Reversible transfer of drug between blood and body tissues occurs across distinct anatomical fluid volumes (% expressed relative to total body weight):

      • Plasma: 5%5\% of body weight

      • Interstitial Water: 16%16\% of body weight

      • Intracellular Water: 35%35\% of body weight

      • Adipose Tissue (Fat): 20%20\% of body weight

      • Transcellular Water: 2%2\% of body weight (includes cerebrospinal fluid [CSF], vitreous humor, peritoneal, pleural, synovial fluids, and GI secretions)


Anatomical body fluid compartments and their relative percentages
  • Plasma and Tissue Protein Binding:

    • Drugs exist in reversible equilibrium between bound and free (unbound) states in plasma.

    • Binding Partners:

      • Serum Albumin: Binds predominantly acidic drugs.

      • α1\alpha_1-Acid Glycoprotein: Binds predominantly basic drugs.

      • Lipoproteins: Bind neutral and highly lipophilic drugs.

    • Fraction Unbound (fuf_u):

      • Only unbound free drug exerts pharmacodynamic activity and crosses vascular endothelial barriers into interstitial/intracellular compartments.

      • Rapid dissociation rates allow protein-bound drug to act as a dynamic reservoir; extremely slow or irreversible binding is functionally equivalent to elimination.

  • Blood-Brain Barrier (BBB) Architecture:

    • Brain capillary endothelial cells are joined by continuous tight junctions, surrounded by a basement membrane and astrocyte foot processes.

    • Hydrophilic or highly polar drugs are strictly excluded from the CNS unless recognized by specialized active transport systems (e.g., L-DOPA\text{L-DOPA} uptake mediated by amino acid transporters).


Structural barrier elements of the blood-brain barrier
  • Rate-Limiting Steps in Distribution:

    • Perfusion-Limited Distribution: Occurs when biological membranes present negligible physical barriers (typical for highly lipophilic molecules). Distribution rate to specific tissues is governed directly by blood flow rate (rapid accumulation in highly perfused organs such as heart, kidneys, liver, and brain).

    • Permeability-Limited Distribution: Occurs when target membranes present significant permeability barriers (typical for polar or charged drugs and large biologics/antibodies). Distribution rate is constrained by membrane permeability rather than organ blood flow.

  • Pharmacokinetic Compartment Models:

    • One-Compartment Model: Assumes rapid, instantaneous distribution of drug throughout plasma and vascularly accessible tissues following intravenous administration, yielding a single exponential elimination slope.

    • Two-Compartment Model: Describes rapid initial distribution into a central compartment (plasma and highly vascularized organs) followed by slow equilibration into a peripheral compartment (e.g., muscle, adipose tissue).

      • Plasma concentration decay curves exhibit two distinct phases: a distribution phase governed by distribution rate constant α\alpha, and a terminal elimination phase governed by elimination rate constant β\beta


Plasma concentration decay curve for a two-compartment model showing alpha distribution and beta elimination phases

Pathways of Biotransformation (Metabolism)

  • Overview and Physiological Rationale:

    • Primary objective: Chemically transform non-polar lipophilic compounds into polar, water-soluble metabolites to enable renal or biliary excretion.

    • Primary organ site: Liver (hepatocytes).

    • Overall elimination process: Elimination=Metabolism+Excretion\text{Elimination} = \text{Metabolism} + \text{Excretion}.

  • Phase I Reactions (Functionalization):

    • Introduces or unmasks polar functional groups (−OH-\text{OH}, −NH2-\text{NH}_2, −COOH-\text{COOH}, −SH-\text{SH}) via oxidation, reduction, or hydrolysis, increasing chemical reactivity for subsequent conjugation.

    • Cytochrome P450 (CYP) Monooxygenase System:

      • Responsible for ∼95%\sim 95\% of all Phase I oxidative biotransformations.

      • Heme-containing iron proteins switching between ferric (Fe3+\text{Fe}^{3+}) and ferrous (Fe2+\text{Fe}^{2+}) states.

      • Major human liver isoforms include CYP3A4 and CYP2D6, displaying broad, overlapping substrate specificities.

      • Exhibits high genetic polymorphism and susceptibility to competitive inhibition or enzyme induction by drugs and diet.

    • Cytochrome P450 Catalytic Cycle:

      • Ferric P450 (Fe3+\text{Fe}^{3+}) binds substrate drug (DH\text{DH}).

      • NADPH-P450 reductase / Cytochrome b5b_5 transfers an electron (e−e^-), reducing iron to ferrous state (Fe2+DH\text{Fe}^{2+}\text{DH}).

      • Molecular oxygen (O2\text{O}_2) binds to yield a Fe2+O2DH\text{Fe}^{2+}\text{O}_2\text{DH} complex.

      • Delivery of a second electron and proton (H+,e−H^+, e^-) generates Fe2+OOH-DH\text{Fe}^{2+}\text{OOH-DH}.

      • Loss of water (H2O\text{H}_2\text{O}) forms a reactive iron-oxoid intermediate (FeO)3+DH(\text{FeO})^{3+}\text{DH}.

      • Oxygen atom is inserted into drug substrate, releasing hydroxylated product (DOH\text{DOH}) and regenerating ferric P450 (Fe3+\text{Fe}^{3+}).


Cytochrome P450 catalytic cycle
  • Non-CYP Phase I Enzymes:

    • Alcohol dehydrogenase, Monoamine oxidase (MAO), Carboxylesterases, Dehydrogenases, Oxidases, Reductases, and Glutathione SS-transferases (GST).

  • Phase II Reactions (Conjugation):

    • Couples a Phase I metabolite or parent drug with an endogenous hydrophilic moiety (e.g., glucuronic acid, glutathione, sulfate, acetate).

    • Conjugated metabolites are generally inactive, highly polar, non-reactive, and easily excreted.

    • Glucuronidation: Catalyzed by UDP-glucuronosyltransferases (UGT), utilizing UDP-glucuronic acid to form drug-glucuronides.

    • Glutathione Conjugation: Catalyzed by Glutathione SS-transferase (GST), transferring glutathione (tripeptide Cys-Glu-Gly with a free reactive thiol −SH-\text{SH} group) to electrophilic reactive drug intermediates, neutralizing potential cellular toxicity.

Mechanics of Drug Excretion

  • Excretion Overview:

    • Excretion is the irreversible physical elimination of unchanged drug or metabolites from the body.

    • Excretory routes: Urine (primary route), Bile (feces), Sweat, Exhaled breath, Breast milk.

  • Processes of Renal Excretion:

    • Total renal clearance is calculated as:

Renal Excretion=Glomerular Filtration+Tubular Secretion−Tubular Reabsorption\text{Renal Excretion} = \text{Glomerular Filtration} + \text{Tubular Secretion} - \text{Tubular Reabsorption}


Schematic representation of filtration, secretion, and reabsorption processes within the nephron
  • 1. Glomerular Filtration:

    • Passive bulk flow through fenestrated glomerular capillaries in the renal corpuscle.

    • Normal Glomerular Filtration Rate (GFR): ∼120 mL min−1\sim 120\,\text{mL\,min}^{-1}. Measured clinically using inulin or endogenous creatinine clearance.

    • Excludes molecules with molecular weight Mr>20,000 g/molM_r > 20{,}000\,\text{g/mol} and plasma protein-bound drug fraction; only free unbound drug is filtered.

  • 2. Active Tubular Secretion:

    • Active, carrier-mediated transport across proximal convoluted tubular cells.

    • Utilizes non-specific transport systems for organic anions (OATs) and organic cations (OCTs).

    • Saturable process subject to competitive drug inhibition. Transport carriers strip drug from plasma proteins as free concentration drops.

  • 3. Tubular Reabsorption:

    • Endogenous nutrients (glucose, vitamins) are actively reabsorbed.

    • Drugs reabsorb predominantly via passive lipid diffusion across tubular epithelium back into peritubular capillaries.

    • Extremely sensitive to lipophilicity and urinary pH (ion trapping). Alkalinization of urine forces weak acid drugs (e.g., aspirin, pKa3.5pK_a 3.5) into ionized conjugate forms (A−\text{A}^-), blocking reabsorption and enhancing urinary clearance. Acidification of urine forces weak bases (e.g., pethidine, pKa8.6pK_a 8.6) into protonated forms (BH+\text{BH}^+), driving excretion.

  • Biliary Excretion and Enterohepatic Recirculation:

    • Active carrier secretion by hepatocytes into bile canaliculi.

    • Favors polar compounds with molecular weight Mr>350 g/molM_r > 350\,\text{g/mol} (especially glucuronide conjugates).

    • Enterohepatic Recirculation: Secreted drug-glucuronides enter the duodenum via the bile duct. Intestinal microflora express enzymes (such as β\beta-glucuronidase) that cleave the glucuronide moiety, releasing free, lipophilic parent drug. The liberated drug is reabsorbed across intestinal mucosa into the portal vein back to the liver, forming a persistent recirculating loop that significantly prolongs terminal elimination half-life.


Biliary drug secretion and intestinal reabsorption via enterohepatic circulation
Principles of Drug Absorption
  • Solubilization Requirements for Oral Absorption:

    • Solid dosage forms must dissolve into solution before systemic absorption can occur; the rate of dissolution often acts as the rate-limiting step for overall absorption.

    • Key physicochemical factors governing solubilization include degree of ionization (pH-dependent), molecular polar hydrophilicity, and overall molecular shape.

    • Polar molecules generally exhibit higher aqueous solubility, whereas non-polar lipophilic molecules exhibit higher membrane permeability.

  • Lipinski's Rule of 5:

    • Predicts that oral absorption is likely to be poor for a small molecule drug candidate if it violates more than one of the following thresholds:

    • There are more than 55 hydrogen bond donors (calculated as the sum of all NH\text{NH} and OH\text{OH} functional groups).

    • There are more than 1010 hydrogen bond acceptors (calculated as the sum of all N\text{N} and O\text{O} atoms).

    • The molecular weight (MrM_r) is greater than 500 g/mol500\,\text{g/mol}.

    • The calculated octanol-water partition coefficient (cLogP\text{cLog}P) is greater than 5$.

  • Mechanisms of Membrane Transport (Diagram Breakdown):

    • Membrane Transport Routes Diagram:

    • Paracellular Diffusion: Movement between adjacent cells, limited to small (M_r < 350\,\text{g/mol})polardrugs.</p></li><li><p><em>PassiveLipidDiffusion</em>:Directmovementthroughthephospholipidbilayerforunchargedlipophilicdrugs.</p></li><li><p><em>Aquaporins</em>:Water−selectivechannelproteinsfacilitatingtransportofwaterandsmallunchargedsolutes.</p></li><li><p><em>Carrier−MediatedTransport</em>:Proteintransporters(activeorfacilitatedpassivediffusion)movingdrugsacrossmembranes.</p></li><li><p><em>Pinocytosis</em>:Fluid−phaseendocytosisengulfingdrugmoleculesintomembranevesicles.</p></li><li><p><strong>Fick′sLawofDiffusionDiagram</strong>:</p></li><li><p>Governspassivelipiddiffusionacrossbiologicalmembranes.</p></li><li><p>Mathematicalexpression:<br>) polar drugs.</p></li><li><p><em>Passive Lipid Diffusion</em>: Direct movement through the phospholipid bilayer for uncharged lipophilic drugs.</p></li><li><p><em>Aquaporins</em>: Water-selective channel proteins facilitating transport of water and small uncharged solutes.</p></li><li><p><em>Carrier-Mediated Transport</em>: Protein transporters (active or facilitated passive diffusion) moving drugs across membranes.</p></li><li><p><em>Pinocytosis</em>: Fluid-phase endocytosis engulfing drug molecules into membrane vesicles.</p></li><li><p><strong>Fick's Law of Diffusion Diagram</strong>:</p></li><li><p>Governs passive lipid diffusion across biological membranes.</p></li><li><p>Mathematical expression:<br>\text{Flux} = \frac{(C1 - C2) \times \text{Area} \times \text{Permeability}}{\text{Thickness}}</p></li><li><p><em>Explanation</em>:Transmembraneconcentrationgradient(</p></li><li><p><em>Explanation</em>: Transmembrane concentration gradient (C1 - C2),surfacearea,andmembranethicknessdirectlydeterminetherateofdrugmovementacrossthelipidlayer.</p></li><li><p><strong>pHTrappingandPartitionHypothesisDiagram</strong>:</p></li><li><p><em>Explanation</em>:Uncharged(non−ionized)formsofweakacids(), surface area, and membrane thickness directly determine the rate of drug movement across the lipid layer.</p></li><li><p><strong>pH Trapping and Partition Hypothesis Diagram</strong>:</p></li><li><p><em>Explanation</em>: Uncharged (non-ionized) forms of weak acids (\text{AH})orweakbases() or weak bases (\text{B})crosslipidmembraneseasily.OnceinacompartmentwithadifferentpH,theyionizeintochargedspecies() cross lipid membranes easily. Once in a compartment with a different pH, they ionize into charged species (\text{A}^-oror\text{BH}^+)thatcannotdiffuseback,resultinginaccumulation("trapping").</p></li><li><p>Equilibriumequations:<br>) that cannot diffuse back, resulting in accumulation ("trapping").</p></li><li><p>Equilibrium equations:<br>\text{AH} \rightleftharpoons \text{A}^- + \text{H}^+<br><br>\text{BH}^+ \rightleftharpoons \text{B} + \text{H}^+

    • Carrier-Mediated & Efflux Transport Diagram:

    • Explanation: Shows uptake transporters facilitating drug entry into blood/tissues, contrasted with efflux pumps (e.g., P-glycoprotein encoded by \text{MDR1})activelypumpingdrugmoleculesoutofmembranecellsbackintotheGIlumen,limitingoverallabsorption.</p></li></ul></li></ul><h5>FactorsAffectingGastrointestinal(GI)Absorption</h5><ul><li><p><strong>AnatomicalFactors</strong>:</p><ul><li><p><strong>Stomach</strong>:Smallsurfacearea() actively pumping drug molecules out of membrane cells back into the GI lumen, limiting overall absorption.</p></li></ul></li></ul><h5>Factors Affecting Gastrointestinal (GI) Absorption</h5><ul><li><p><strong>Anatomical Factors</strong>:</p><ul><li><p><strong>Stomach</strong>: Small surface area (\sim 1\,\text{m}^2).</p></li><li><p><strong>SmallIntestine</strong>:Verylargesurfacearea().</p></li><li><p><strong>Small Intestine</strong>: Very large surface area (\sim 200\,\text{m}^2)duetomicrovilli,highpermeability,andrichbloodsupply.</p></li><li><p><strong>LargeIntestine</strong>:Intermediatesurfaceareawithlongertransittime() due to microvilli, high permeability, and rich blood supply.</p></li><li><p><strong>Large Intestine</strong>: Intermediate surface area with longer transit time (10\text{--}36\,\text{hours}).

  • Transit Time & Formulation Factors:

    • Gastric emptying rate determines transit speed to the small intestine; delay by food (especially lipids) provides additional time for poorly soluble drugs to dissolve.

    • Binding interactions (e.g., tetracycline chelating with divalent metal ions \text{M}^{2+})preventabsorption.</p></li></ul></li><li><p><strong>First−PassMetabolism</strong>:</p><ul><li><p>Metabolisminthegutlumen(flora),gutwall(CytochromeP450,monoamineoxidase),andliverreducesbioavailabledrugpriortoreachingsystemiccirculation.</p></li></ul></li></ul><h5>DrugDistribution</h5><ul><li><p><strong>BodyFluidCompartmentsDiagram</strong>:</p><ul><li><p><em>Explanation</em>:Reversibletransferofunbounddrugacrossdistinctbodyfluidcompartmentsexpressedaspercentageoftotalbodyweight:</p></li><li><p>Plasma:) prevent absorption.</p></li></ul></li><li><p><strong>First-Pass Metabolism</strong>:</p><ul><li><p>Metabolism in the gut lumen (flora), gut wall (Cytochrome P450, monoamine oxidase), and liver reduces bioavailable drug prior to reaching systemic circulation.</p></li></ul></li></ul><h5>Drug Distribution</h5><ul><li><p><strong>Body Fluid Compartments Diagram</strong>:</p><ul><li><p><em>Explanation</em>: Reversible transfer of unbound drug across distinct body fluid compartments expressed as percentage of total body weight:</p></li><li><p>Plasma:5\%</p></li><li><p>InterstitialWater:</p></li><li><p>Interstitial Water:16\%</p></li><li><p>IntracellularWater:</p></li><li><p>Intracellular Water:35\%</p></li><li><p>Fat:</p></li><li><p>Fat:20\%</p></li><li><p>TranscellularWater(CSF,synovial,pleuralfluid):</p></li><li><p>Transcellular Water (CSF, synovial, pleural fluid):2\%</p></li></ul></li><li><p><strong>Perfusionvs.PermeabilityLimitationsDiagram</strong>:</p><ul><li><p><em>Perfusion−Limited</em>:Membraneofferslittlebarrierresistance;distributionrateisdeterminedbytissuebloodflow(typicalforlipophilicdrugs).</p></li><li><p><em>Permeability−Limited</em>:Membranepresentsasignificantbarrier;distributionrateisdeterminedbymembranepermeability(typicalforpolardrugs/antibodies).</p></li></ul></li><li><p><strong>CompartmentalDistributionModelsDiagram</strong>:</p><ul><li><p><em>One−CompartmentModel</em>:Rapid,instantaneousdistributionthroughoutbodyfluids;plotof</p></li></ul></li><li><p><strong>Perfusion vs. Permeability Limitations Diagram</strong>:</p><ul><li><p><em>Perfusion-Limited</em>: Membrane offers little barrier resistance; distribution rate is determined by tissue blood flow (typical for lipophilic drugs).</p></li><li><p><em>Permeability-Limited</em>: Membrane presents a significant barrier; distribution rate is determined by membrane permeability (typical for polar drugs/antibodies).</p></li></ul></li><li><p><strong>Compartmental Distribution Models Diagram</strong>:</p><ul><li><p><em>One-Compartment Model</em>: Rapid, instantaneous distribution throughout body fluids; plot of\ln[\text{Drug}]vs.timeshowsasingleeliminationslope.</p></li><li><p><em>Two−CompartmentModel</em>:Rapidinitialdistributionintocentralcompartment(plasma/high−perfusionorgans),followedbyaslowdistributionphase(vs. time shows a single elimination slope.</p></li><li><p><em>Two-Compartment Model</em>: Rapid initial distribution into central compartment (plasma/high-perfusion organs), followed by a slow distribution phase (\alpha)intoperipheralcompartment(muscle/fat)beforeterminaleliminationphase() into peripheral compartment (muscle/fat) before terminal elimination phase (\beta).</p></li></ul></li></ul><h5>DrugMetabolismandExcretion</h5><ul><li><p><strong>MetabolicPathwayDiagram</strong>:</p><ul><li><p><em>Explanation</em>:Primaryrationaleisconvertinglipophilicdrugsintowater−solublemoleculesforexcretion.</p></li><li><p><em>PhaseI</em>:Oxidation(viaCytochromeP450/CYPenzymeslike).</p></li></ul></li></ul><h5>Drug Metabolism and Excretion</h5><ul><li><p><strong>Metabolic Pathway Diagram</strong>:</p><ul><li><p><em>Explanation</em>: Primary rationale is converting lipophilic drugs into water-soluble molecules for excretion.</p></li><li><p><em>Phase I</em>: Oxidation (via Cytochrome P450 / CYP enzymes like\text{CYP3A4}),reduction,orhydrolysisintroducing/exposingareactivefunctionalgroup.</p></li><li><p><em>PhaseII</em>:ConjugationofPhaseIintermediatewithhydrophilicbiomolecules(e.g.,UDP−glucuronicacidviaUDP−glucuronosyltransferaseorglutathioneviaglutathioneS−transferase)producingapolar,inactiveconjugate.</p></li></ul></li><li><p><strong>RenalExcretionProcessesDiagram</strong>:</p><ul><li><p><em>Explanation</em>:Nephronstructureshowingthreecoreprocesses:</p></li></ul><ol><li><p><em>GlomerularFiltration</em>:Passivefiltrationattherenalcorpuscleforunbounddrug(), reduction, or hydrolysis introducing/exposing a reactive functional group.</p></li><li><p><em>Phase II</em>: Conjugation of Phase I intermediate with hydrophilic biomolecules (e.g., UDP-glucuronic acid via UDP-glucuronosyltransferase or glutathione via glutathione S-transferase) producing a polar, inactive conjugate.</p></li></ul></li><li><p><strong>Renal Excretion Processes Diagram</strong>:</p><ul><li><p><em>Explanation</em>: Nephron structure showing three core processes:</p></li></ul><ol><li><p><em>Glomerular Filtration</em>: Passive filtration at the renal corpuscle for unbound drug (M_r < 20{,}000\,\text{g/mol}).</p></li><li><p><em>ActiveTubularSecretion</em>:Non−specificactivetransportersinproximaltubulessecretingorganicanionsandcationsintothetubulelumen.</p></li><li><p><em>PassiveTubularReabsorption</em>:Passivediffusionofuncharged/lipophilicdrugsbackintoblood;dependentonurinarypH.</p></li></ol><ul><li><p>Netexcretionformula:<br>).</p></li><li><p><em>Active Tubular Secretion</em>: Non-specific active transporters in proximal tubules secreting organic anions and cations into the tubule lumen.</p></li><li><p><em>Passive Tubular Reabsorption</em>: Passive diffusion of uncharged/lipophilic drugs back into blood; dependent on urinary pH.</p></li></ol><ul><li><p>Net excretion formula:<br>\text{Renal Excretion} = \text{Filtration} + \text{Secretion} - \text{Reabsorption}

  • Biliary Excretion & Enterohepatic Recycling Diagram:

    • Explanation: Active secretion of polar, higher molecular weight (M_r > 350\,\text{g/mol}$$) compounds from liver into bile duct and gallbladder. Once delivered to the small intestine, conjugated drug can be hydrolyzed by gut flora and reabsorbed via the portal vein back to the liver, establishing a recycling loop.